Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I suspect this is a case of people who know people and afew who have done some amazing leg work for everyone else in the telegram chat
There buys, enough said.
There is no way of knowing whether these transactions are share sales or purchases. The trend appears to be upwards at present. I await with interest to see what next week holds.
The majority are delayed trades from yesterday Jimmy and look likely to be buys looking at the times and sp. definitely the reason it has increased to a buy of 15 last few days been some chunky trades for sure but a lot of them are buys for sure..!!
Dear me does someone somewhere know something. That's an awful lot of shares sold there on a Friday afternoon
Thank you jmfw.
I found the AccuStem link earlier today on Twitter. I agree with you that the link between TILS and OKYO is purely coincidental (same key personnel in both companies). Nevertheless, my hasty research on Monday suggests that OKYO seems to be a good investment for the future.
Regards.
https://beta.companieshouse.gov.uk/company/12647178
TLW, for info, this covered on TILS board under thread "Thoughts on OKYO Speculation" on 22 July. Majority view is that there will be no involvement between Tils & Okyo. My own view is that the Tils spin off (Stemprinter) will reverse into accuSTEM, which is a company set up by the management in June (I think).
The share price has risen today to a level approaching last Monday. Surprisingly, there hasn't been a single relevant comment either on this board or the equivalent board on advfn. There has been some unfortunate posting by someone who appears to be suffering from a form of cognitive disfunction on the advfn board. There is a relentless onslaught of cut and paste relating to a different company from that individual. However, there is nothing from him/her on the quiet board of that particular company ?
More to the point, I invested in Okyo Pharma following the recent abrupt recent rise in share price. I may have wrongly assumed that there is a link between OKYO and the forthcoming TILS decoupling? There is an uncanny overlap of key personnel between the two companies. Perhaps this is just a coincidence? However, I intend to keep my OKYO shares for the time being, as I see a reasonable potential for a further upgrade in share price in the not too distant future.
This guy. Worked on that rto why bring him out of retirement now? DIRECTORATE CHANGE
OKYO Pharma Limited ("OKYO" or the "Company") today announces that John Brancaccio has been appointed as a non-executive director of the company with immediate effect. Gregor MacRae is simultaneously standing down as a director of the Company with immediate effect.
Mr Brancaccio (aged 72) is a retired certified accountant. Mr Brancaccio graduated from Selton Hall University in New Jersey with a BA in Accountancy prior to joining Touche Ross & Co in 1970. Having attained the position of audit supervisor, Mr Brancaccio went into industry in 1974.
Most recently, prior to his retirement in 2017, Mr Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc. overseeing a portfolio of companies in the medical device area and managing the private financing rounds for each company. This portfolio was in excess of $100 million in invested funds.
Mr Brancaccio has extensive public company non-executive experience and is currently a member of the boards of directors of Rasna Therapeutics, Inc., Hepion Pharmaceuticals, Inc., and Cardiff Oncology, Inc.
John will chair the Audit and Risk Committee of the Board (which also comprises Willy Simon) and will sit as a member of the Remuneration Committee (which also comprises Willy Simon as chairman).
Willy Simon, Chairman of OKYO, said "We are delighted that John has joined the Board of OKYO. His expertise will be of great value to us. He is a great addition to the Board at a very important time for the group. I thank Gregor for his contribution to the Board and the Company and wish him well in his other interests".
https://www.lse.co.uk/rns/WAFM/proposed-disposal-special-dividend-notice-of-gm-qu3wrat8o2te7oh.html
Take out the space
https://t.me/joi nchat/HkgNOBegu0f_uURKbm3GNw
**********************HkgNOBegu0f_uURKbm3GNw
If that ends up here and gets sold for + 1 billion... then its huge multiplies of the current SP. If that isn't worth a punt I don't know what is.
And there are very very strong links pointing to it being the case
I’m not trying to belittle Okyo, on the contrary, I think there product could be multi billion blockbusters especially the non opioid pain killer but they still have along way to go, Tils have already trod that road. Nuf said from me now
The current minimum fee for admission to the AIM (up to £5m of capitalisation) is £6,720, while the current annual fee is £5,350
Plus cost of funding raising which will happen either way.
GC did actually say StemprintER would stand-alone in its own company and be able to raise funds on its own as I’m sure he cannot transfer monies from tils. There’s nearly 3 times the shares in Okyo than tils so how is he going to do that. Only far way is to form new plc not buy a listing in a RTO. Anyway we shall see soon enough.
@jarv55 - Can you assist?
Had a quick peek but may be i'm missing it.
Looking for it myself mate. Someone may have mentioned it on ADVFN
GC actually stated in interview that STEM and SPARE would be demerger'd from TILS and established within a Geonomics company in it's own right. It's all there. I'll agree that he said TILS shareholders would get 100% of the value of STEM but he also said that TILS holders would get a 1:1 share in the new entity.
You cannot list a new company on the main market without a significant raise and associated listing costs so ZERO dilution to TILS holders is an impossibility
whats the telegram grp link pls?
"unless he wipes out existing Okyo shareholders.IMO"
So, he plans to wipe out his 54% holding of OKYO does he? Don't think GC is daft - do you?
Not a chance as GC stated Stem will be standalone, unless he wipes out existing Okyo shareholders.IMO
How do u think this would work out for OKYO holders. I am in TILS but not yet in OKYO. Thx.
Oh my god. I can’t watch because I haven’t sold a bean yet. This is so stressful!